Inactivation of the p53 tumour suppressor, either by mutation or by overexpression of its inhibitors Hdm2 and HdmX is the most frequent event in cancer. Reactivation of p53 by targeting Hdm2 and HdmX is therefore a promising strategy for therapy. However, Hdm2 inhibitors do not prevent inhibition of p53 by HdmX, which impedes p53-mediated apoptosis. Here, we show that p53 reactivation by the small molecule RITA leads to efficient HdmX degradation in tumour cell lines of different origin and in xenograft tumours in vivo. Notably, HdmX degradation occurs selectively in cancer cells, but not in non-transformed cells. We identified the inhibition of the wild-type p53-induced phosphatase 1 (Wip1) as the major mechanism important for full engagement of p53 activity accomplished by restoration of the ataxia telangiectasia mutated (ATM) kinase-signalling cascade, which leads to HdmX degradation. In contrast to previously reported transactivation of Wip1 by p53, we observed p53-dependent repression of Wip1 expression, which disrupts the negative feedback loop conferred by Wip1. Our study reveals that the depletion of both HdmX and Wip1 potentiates cell death due to sustained activation of p53. Thus, RITA is an example of a p53-reactivating drug that not only blocks Hdm2, but also inhibits two important negative regulators of p53 -HdmX and Wip1, leading to efficient elimination of tumour cells.
By regulating cell-cycle control, DNA repair and apoptosis, p53 serves as a major gatekeeper of tumour suppression. Upon oncogene activation, p53 is released from its negative regulators, Hdm2 and HdmX, becomes activated and induces transcription of its target genes.
1 Hdm2 and HdmX are structurally alike and both inhibit the transcriptional activity of p53 by direct binding. In addition, Hdm2 possesses an intrinsic E3 ubiquitin ligase activity, which targets p53 for proteasomal degradation. 1 Upon certain types of DNA damage Hdm2 autoubiquitinates itself and HdmX, leading to the degradation of both proteins, [2] [3] [4] [5] allowing continuous p53 activation.
The function of p53 is impaired in the majority, if not all human cancers, either by mutation, or by functional deregulation of its inhibitors, Hdm2 and HdmX which are overexpressed in many tumours. 6, 7 Major efforts aimed at p53 reactivation have been focused on targeting the Hdm2/p53 interaction, [8] [9] [10] the enzymatic activity of Hdm2, 11 or restoring mutant p53 function. 12 Several lines of evidence highlight the importance of developing inhibitors towards HdmX, since downregulation of HdmX by means of siRNA in cancer cell lines induces p53, suppresses colony outgrowth 13 and reduces tumour xenograft growth.
14 Importantly, HdmX forms heterodimers with Hdm2, which enhances the E3 ligase activity of Hdm2, leading to decreased p53 levels. 15 A recent study has demonstrated that the p53-reactivating compound nutlin3a has a 30-fold lower efficiency in disrupting the p53/HdmX complex compared with p53/Hdm2. 16 Furthermore, activation of p53 after nutlin3a treatment is significantly enhanced upon downregulation of HdmX by siRNA in a number of human tumour cell lines, 16 which is in line with the notion that downregulation of HdmX is necessary for complete p53 activation. 17 There have been reports of short peptides inhibiting HdmX/p53; 18 however, the clinical application of peptides is not optimal due to their proteolytic degradation and insufficient cellular uptake. Recently, the chemical inhibitor of HdmX/p53 interaction, SJ-172550 has been found, which displays additive effects in cancer cells when combined with an Hdm2 inhibitor. exhibits oncogenic features. It is overexpressed in a vast number of tumours 20 and is important for tumour stem cell survival. 21 Wip1 is a direct transcriptional target of p53 22 which inhibits p53, creating a negative feedback loop. Wip1 counteracts p53 activation following DNA damage on several levels, including reversion of the activating p53 phosphorylation at S15 23 and stabilization of p53's negative regulators Hdm2 and HdmX by dephosphorylating sites that trigger their proteasomal degradation. 24 Importantly, the two major DNAdamage sensors ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) are targeted by Wip1, blocking DNA-damage signalling. 25 This interference with the DNA damage response confers resistance to standard treatments in tumours overexpressing Wip1 and therefore makes Wip1 an attractive target for anti-cancer therapy. 26 Here, we report that p53 induced by RITA, a chemical activator of p53, efficiently counteracts the potent oncogenes Wip1 and HdmX by reducing their levels in cancer cells of different origin. This disables the p53/Wip1 negative feedback loop and prevents inhibition of p53 by HdmX, thus facilitating robust apoptosis induction.
Results
RITA-activated p53 induces depletion of HdmX in tumour cells. Comparison of the biological effects of two inhibitors of the p53/Hdm2 interaction, nutlin3a and RITA showed that in HCT116 and MCF7 cells, RITA induces apoptosis whereas nutlin3a triggers mainly growth arrest. 27, 28 Several studies have demonstrated that HdmX impedes the induction of apoptosis upon inhibition of Hdm2 by nutlin3a in MCF7 cells. We found that HdmX is potently downregulated after RITA treatment, but not after nutlin3a treatment (Figures 1a and 5c ). Kinetic analysis demonstrated that RITA treatment reduced HdmX protein levels in MCF7 and HCT116 cells in a time-dependent manner ( Figure 1b ). In addition, we observed oscillation of Hdm2 levels (Figures 1b and 3b), which is in line with our previous study. 29 Several reports have demonstrated Hdm2 oscillation upon p53 activation by DNA damage due to opposing processes: transcriptional activation of its expression by p53 and enhanced proteasomal degradation. 30 Next, we investigated whether the downregulation of HdmX was p53-dependent. We compared the effect of RITA in the wild-type p53-expressing HCT116 cells with that in the isogenic HCT116 p53-null derivative, HCT116 TP53À/À. In contrast to p53-positive cells, HdmX was not affected by RITA in p53-null cells (Figure 1b) . Concordantly, HdmX was not depleted by RITA treatment in two other p53-null cell lines, H1299 and Saos-2 (Figure 1c) , suggesting that the effect of RITA on HdmX is p53-dependent. This conclusion was further corroborated employing the previously described p53-inhibitor pifithrin-a (PFT-a), 31 which abolished HdmX downregulation in HCT116 and MCF7 cells (Figure 1d) . We extended our studies using a set of wild-type p53-expressing human tumour cell lines of different origin. The observed decline of HdmX levels upon RITA treatment was unambiguous in the majority of these cell lines (Figure 2a) .
To investigate the importance of our finding in a more physiological setting, we examined the level of HdmX upon RITA treatment in human xenografts grown in SCID mice. Notably, we detected a decline of HdmX in p53-positive HCT116, but not in HCT116 TP53À/À tumour xenografts (Figure 1e ).
Since HdmX is important to keep p53 activity low in the absence of stress in untransformed cells, depletion of HdmX might lead to toxicity in normal tissues. Therefore, we tested whether the decline of HdmX upon RITA treatment occurs in untransformed cells. As previously reported, the p53 protein level is not elevated by RITA in untransformed cells, 9, 27 and in line with that we did not detect significant changes in HdmX levels in untransformed cell lines, including normal human diploid fibroblasts (NHDF) and mammary epithelial cells, 184A1 and MCF10A (Figures 1f and g ). Thus, HdmX (f) HdmX depletion facilitates the killing of tumour cells by RITA, as detected using long-term viability assay. Cells were seeded at low density and exposed to 1 mM RITA for 24 h, the medium was changed and the cells were grown for 7 days. The colonies were then stained with crystal violet RITA-activated p53 inhibits Wip1 and HdmX C Spinnler et al downregulation requires p53 activation by RITA, which only occurs in oncogene-expressing cells. 9, 27 Taken together, these results demonstrate that RITA induces p53-dependent HdmX downregulation exclusively in tumour cells.
Downregulation of HdmX correlates with RITA-induced apoptosis. HdmX levels after RITA treatment were examined in a panel of human tumour cell lines of different origin, including breast, lung and colon carcinoma, as well as lung fibrosarcoma and osteosarcoma. In the majority of the cell lines, we observed a decline of HdmX (as well as Wip1, which will be discussed later) after 8 h of RITA treatment, while the osteosarcoma SJSA and the colon carcinoma RKO were exceptions (Figure 2a ). In these cells, HdmX levels did not decrease even after 24 h of treatment ( Figure 2b ).
Next, we tested whether there is a correlation between the decrease of HdmX and RITA sensitivity. In line with previously published data, we observed that the majority of wild-type p53-expressing human tumour cell lines underwent apoptosis after RITA treatment, as evidenced by the induction sub-G1 fraction (Figure 2c ). However, we did not detect a significant induction of apoptosis in SJSA and RKO lines (Figure 2c) . Thus, HdmX downregulation correlated with the apoptosis induction by RITA in human tumour cell lines.
The results presented above suggest that HdmX downregulation contributes to the efficient apoptosis induction by RITA. To test this further, we assessed whether depletion of HdmX by shRNA enhanced the biological effect of RITA. In line with Linares et al., 15 HdmX depletion led to an elevated p53 level. This results in stronger p53 induction upon RITA treatment (Figure 2d ). Moreover, HdmX depletion significantly enhanced apoptosis induction by p53 upon treatment with RITA ( Figure 2e ). We also observed augmented growth suppression in a long-term growth suppression assay (Figures 2f and 6c) . Taken together, these results clearly show that the potent depletion of HdmX contributes to robust apoptosis induction and thereby aids the anti-tumour effects conferred by RITA-activated p53.
The decrease of HdmX protein levels occurs through a proteasome-dependent mechanism independently of Hdm2. As HdmX is a long-lived protein (see Figure 3a ), the reduction of its level observed already 4 h after treatment suggests enhanced protein degradation. Therefore, we examined whether RITA treatment leads to decreased HdmX protein stability. The half-life of HdmX was significantly shortened upon RITA treatment, indicating active degradation (Figure 3a) . Next, we studied whether inhibition of the proteasome by MG132 could stabilize HdmX, and indeed the protein levels were rescued (Figure 3b) .
Hdm2 is the most prominent negative regulator of HdmX. It is an E3 ligase that, upon certain signals, forms a heterodimer with HdmX, leading to its ubiquitination and subsequent degradation by the proteasome. 4, 5, 32 To address whether Hdm2 is involved in HdmX downregulation after RITA treatment, we depleted Hdm2 by means of siRNA. As expected, HdmX and p53 protein levels were elevated upon Hdm2 knockdown. RITA-induced downregulation of HdmX levels was, however, not compromised in the absence of Hdm2 (Figure 3c) . Similarly, inhibition of Hdm2 by overexpression of dominant negative Hdm2 mutants did not rescue the level of HdmX (data not shown). We conclude that RITA-induced downregulation of HdmX is proteasomedependent, but is not mediated by Hdm2.
ATM is essential for HdmX downregulation by RITA. Several studies have demonstrated that DNAdamage signalling induces degradation of HdmX. 4, 5 RITA has been shown to induce p53-dependent DNA damage signalling, including ATM activation. 33 As ATM directly phosphorylates and thereby destabilizes HdmX, we tested whether ATM is involved in HdmX downregulation. ATM depletion did not influence p53 induction by RITA, suggesting that DNA damage signalling is downstream of p53 (Figure 4a ). However, HdmX degradation was substantially inhibited (Figure 4a) . Further, pretreatment with the selective ATM-inhibitor KU55933 partially prevented the degradation of HdmX (Figure 4b ), suggesting ATM involvement. Since the rescue was incomplete, we cannot rule out the possibility of involvement of other kinases such as ATR. 34 To confirm ATM involvement, we investigated its phosphorylation upon RITA treatment. ATM phosphorylation was increased, as demonstrated by western blotting and immunocytochemistry (Figures 4c and d) , supporting the notion of ATM activation. In line with this, HdmX phosphorylation at S367 and S403 increased (Figure 4e ). To further address the importance of these phosphorylations for RITAinduced HdmX degradation, we assessed whether mutation of serine residues can rescue HdmX levels. In contrast to wild- After RITA treatment for 8 h, immunoprecipitation was performed using anti-HA or non-specific control antibodies. RITA induces phosphorylation of wild-type HdmX at S367 and S403 but not of HdmX-TM. (f) HdmX-TM that cannot be phosphorylated by ATM is protected from degradation induced by RITA treatment. HdmX levels were assessed in MCF7 cells stably expressing a non-phophorylatable triple mutant of HdmX pretreated with RITA for 3 h, followed by cycloheximide treatment for the indicated time spans type HdmX (Figure 3a) , the half-life of non-phosphorylatable triple mutant HdmX-TM carrying S342A, S367A and S403A substitutions did not decrease after RITA treatment (Figure 4f ). These data demonstrate that signalling via ATM is essential for RITA-induced depletion of HdmX.
p53-dependent downregulation of Wip1 mRNA and protein. Activation of ATM in cancer cells is frequently neutralized by p53-activated Wip1, 23 which inhibits ATM and p53 by removing activating phosphorylations. 24 Microarray analysis of gene expression induced by RITA in MCF7 cells revealed potent downregulation of PPM1D, while treatment with nutlin3a led to its induction (Figure 5a ). This was confirmed by quantitative real-time PCR (qPCR) (Figure 5b ). In addition, treatment with the p53 activator 5-FU also resulted in PPM1D induction (Figure 5b ). Consistent with these results, the level of Wip1 protein was induced by nutlin3a and 5-FU, and drastically decreased upon RITA treatment (Figure 5c ).
We found a strong correlation between the decrease of HdmX and Wip1 and the induction of apoptosis in the panel of cancer cell lines (Figures 2a and c) . Importantly, neither HdmX nor Wip1 were downregulated after RITA treatment in RKO and SJSA cells, (Figures 2a and 5d ). Similar to HdmX, the effect on Wip1 was p53 dependent, and was not observed in p53-null cells (Figure 5e ). Wip1, most probably due to incomplete depletion of Wip1 by shRNA (Figure 6a ). Our results presented above (Figure 3b ) showed clear proteasome dependence of RITA-induced HdmX downregulation. Thus, we addressed the question, whether HdmX decrease observed upon Wip1 depletion shows the same characteristics. Using parental HCT116 cells as a reference, we estimated that HCT116-Wip1 shRNA cells exhibit 65% of HdmX protein levels. Blocking the proteasome with MG132 up to 8 h gradually restored HdmX levels to 95% (Figure 6b) .
Wip1 depletion results in
Our results suggest that Wip1 inhibition is important for the p53-mediated biological response in cancer cells. As shown in Figure 6c , downregulation of Wip1 by means of shRNA facilitated the growth suppression effect of nutlin3a and RITA in MCF7 cells, assessed by a long-term growth suppression assay. Since Wip1 decrease seems to be crucial for HdmX degradation, we expressed ectopic Wip1 in U2OS cells. We found that Wip1 overexpression prevents HdmX degradation after RITA treatment (Figure 6d) .
Taken together, our data show that Wip1 is efficiently downregulated in a p53-dependent manner upon RITA treatment. This has a crucial role in the decrease of HdmX protein levels and contributes to the efficient growth suppression by pharmacologically activated p53. 
Discussion
Diverse alterations, which inactivate the p53 tumour suppressor function in cancers with non-mutated TP53, converge on two p53 inhibitors, Hdm2 and HdmX. Since HdmX and Hdm2 regulate p53 independently of each other and act synergistically, inhibition of both Hdm2 and HdmX is required for full p53 activation. 35 This makes both proteins important targets for cancer therapy. Several small molecules inhibiting Hdm2 have been identified; however, these do not affect HdmX, impeding their efficiency, in particular in tumours with overexpressed HdmX. 16 An inhibitor of the HdmX/p53 interaction, SJ-172550 has been described recently; 19 it does not kill cancer cells on its own, but has an additive effect when combined with Hdm2 inhibitors. However, simultaneous targeting of Hdm2 and HdmX by a single molecule has not yet been reported.
In the present study, we found that in addition to preventing the p53/Hdm2 interaction, the small molecule RITA 9 induces a potent destabilization of HdmX protein in cancer cells in vitro and in vivo, in a p53-dependent manner.
Our results suggest that active ATM is required for HdmX downregulation by RITA. Several studies have demonstrated that DNA damage signalling regulates HdmX and Hdm2 protein stability. 3, 4 The checkpoint kinase ATM and its downstream kinase Chk2 induce phosphorylation of Hdm2 2 and HdmX, 5 leading to their degradation. Our data showing partial rescue of HdmX level upon RITA treatment by both ATM knockdown and the ATM-inhibitor KU55933 supports the involvement of ATM in HdmX downregulation. This notion was further strengthened by our finding that the HdmX mutant that cannot be phosphorylated by ATM was rescued from RITA-induced degradation.
p53 induces DNA damage signalling upon activation by RITA. 33 Notably, it appears that this p53 induction is not dependent on DNA damage signalling, since ATM inhibition did not prevent it. These data therefore suggest that induction of DNA damage signalling occurs downstream of p53.
Further elucidation of the factors involved in DNA damage signalling upon RITA treatment allowed us to identify the involvement of the Wip1 phosphatase in HdmX depletion. It has been reported that Wip1 can directly reverse ATMmediated phosphorylation of HdmX, which leads to its stabilization. 24 We observed substantial Wip1 downregulation on protein and mRNA levels upon p53 activation by RITA. Further, our results showed that inhibition of Wip1 has a causal role in the decrease of HdmX, suggesting that the low level of Wip1 helps to unleash HdmX degradation following p53 activation by RITA.
Based on our results we suggest a model (Figure 6e ) in which inhibition of Wip1 by pharmacologically activated p53 creates a positive feedback loop uncoupling p53 from its negative regulators Hdm2 and HdmX. RITA-activated p53 represses the expression of its own inhibitor Wip1, which confers robust activation of p53 by acting on several levels. First, it restores active ATM, which phosphorylates p53, thereby activating it. Second, ATM-mediated phosphorylation of HdmX induces its degradation, negating HdmX-mediated inhibition of p53. Further, in the absence of Wip1 the activating phosphorylation of p53 and inhibitory phosphorylation of HdmX by ATM cannot be removed, which amplifies the signal, triggering full-scale p53 activation.
Normal cell homeostasis requires p53 activity to be kept at bay in the absence of stress. This is achieved by a combination of two negative feedback loops, the one between p53 and Hdm2/HdmX, and that between p53, ATM and Chk2, mediated by Wip1. Both these feedback loops are corrupted in cancers, as evidenced by overexpression and amplification of Hdm2, HdmX and Wip1 in numerous cancers that do not carry TP53 mutations. We demonstrate that pharmacological reactivation of p53 by RITA is able to counteract this imbalance and restore an appropriate p53 response, ultimately leading to apoptosis in tumour cells.
As inhibition of Wip1, Hdm2 and HdmX by a single small molecule is unprecedented, RITA might open a novel therapeutic approach for tumours that are dependent on the overexpression of these factors. In line with this notion, high HdmX levels have been shown to correlate with RITA sensitivity in a panel of breast cancer lines. 36 Simultaneous inhibition of HdmX, Hdm2 and Wip1 might be an essential component for anti-cancer therapies targeting p53. This capability of p53 might allow us to manage with the daunting challenge of anti-cancer therapy -diverse genetic abnormalities in individual cancers.
It is worth noting that in accordance with the absence of p53 activation we did not observe inhibition of HdmX in nontransformed cells by RITA, suggesting that the possibility of toxic effects of RITA in normal cells due to HdmX inhibition is low.
Our finding that Wip1 was repressed upon RITA treatment in a p53-dependent manner is very intriguing. It implies that the p53-mediated negative feedback loops insuring survival of cells following stress signalling could be reversed under certain conditions. We have previously shown that RITAinduced p53 activation can block the pause-and-repair survival pathway mediated by induction of p21. 28 In this study, we demonstrated that the p53/Wip1 negative feedback loop that negates p53 activation could be converted to a positive feedback loop that potentiates p53 activity. This opens a possibility to irreversibly shift the survival-death balance and to produce a robust apoptotic outcome, leading to elimination of tumour cells.
Notably, treatment with nutlin3a did not lead to downregulation of HdmX or Wip1 levels in HCT116 and MCF7 cells. In order to address the mechanism underlying the differential regulation of Wip1 by RITA and nutlin3a, that is, repression versus induction, respectively, we analysed the contribution of several p53 cofactors that are differentially regulated by RITA and nutlin3a, including hnRNP K 28 and HIPK2. 29 However, our data did not support the involvement of these factors (data not shown). An interesting example of a transcription factor, which can both activate and repress the same genes upon binding to their promoters is MyoD. Depending on its interaction with HDAC1 or LSD1 at the promoter of its target genes, MyoD can repress or activate genes, respectively. 37, 38 A similar mechanism could be engaged in the switch between p53-mediated activation and repression of its target gene Wip1. Since there are 450 known p53 partner proteins, which can modulate p53-mediated regulation of gene expression, a high throughput proteomic approach is required to identify such a cofactor(s).
We showed that HdmX and Wip1 downregulation contribute to the induction of apoptosis by p53. As previously reported, nultin3a induces growth arrest in cell lines with high HdmX expression. 28 Upon downregulation of HdmX by shRNA or by combinational treatment with DNA damaging drugs that induce HdmX degradation, nutlin3a induces apoptosis, 16 suggesting that neutralization of the inhibitory effect of HdmX is crucial for the induction of apoptosis by p53. This notion is corroborated by our results showing that shRNA-mediated depletion of HdmX induced p53 levels and enhanced apoptosis upon RITA treatment. Further, Wip1 depletion facilitated growth suppression by nutlin3a, supporting the notion that simultaneous targeting of both Wip1 (this study) and HdmX 16 is required for a full-scale induction of apoptosis upon inhibition of Hdm2.
Two cell lines in which RITA treatment did not induce apoptosis, namely, RKO and SJSA, showed neither Wip1 and HdmX downregulation, nor Hdm2 oscillation. It is plausible that certain undefined defects in the p53 pathway may account for the difference in response to RITA in these cell lines. Further studies will help to elucidate these issues.
In conclusion, our study provides several lines of evidence showing that in addition to blocking the inhibitory effects of Hdm2 on p53, activation of p53 by RITA simultaneously abrogates the two oncogenes, Wip1 and HdmX, creating a positive feedback loop, which potentiates apoptosis induction by p53. These findings open an approach for the development of anti-cancer drug(s) with a broader spectrum than drugs that target only Hdm2.
